目的 探讨元胡止痛胶囊治疗膝骨性关节炎的临床疗效.方法 选取2015年1月至2016年12月在本院骨科门诊膝骨性关节炎患者60例,按照随机法分为实验组(30例)和对照组(30例),实验组予以元胡止痛胶囊及玻璃酸钠联合治疗,而对照组则采用塞来昔布与玻璃酸钠联合治疗,观察两组患者膝关节治疗前后的疼痛评分、WOMAC关节炎指数、OA严重程度指数(ISOA)以及两组治疗期间及治疗观察后的药物不良反应情况.结果 实验组患者治疗后的疼痛评分[(3.21±1.06)]、WOMAC关节炎指数[(80.67±29.85)]、OA严重程度指数(ISOA)[(4.69±0.83)],同对照组治疗后的疼痛评分、WOMAC关节炎指数及OA严重程度指数(ISOA)[(5.39±2.03)、(92.56±31.39)、(5.22±0.57)]比较差异有统计学意义(P＜0.05).两组患者药物不良反应率(实验组12.00％,对照组14.81％)比较,差异无统计学意义(P＞0.05).结论 元胡止痛胶囊联合玻璃酸钠治疗膝关节骨性关节炎疗效好,可有效改善患者关节功能评分,减轻患者疼痛,是中医药治疗该类疾病的较好选择之一.%Objective To explore the clinical efficiency of Yuanhu Zhitong capsule in patients with osteoarthritis.Methods Sixty patients with osteoarthritis in Department of Orthopedics of our hospital from January 2015 to December 2016 were randomly divided into experimental group and control group.The experimental group was treated with Yuanhu Zhitong capsule and sodium hyaluronate,while the control group was treated with celecoxib and sodium hyaluronate.And the function of knee joint was assessed with the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) and index severity of osteoarthritis (ISOA),the adverse reactions were recorded.Results The VAS score in the experimental group after treatment was (3.21±1.06),the WOMAC osteoarthritis index was (80.67±29.85),and index severity of osteoarthritis (ISOA)was (4.69±0.83),which were significantly lower than those in the control group [(5.39±2.03),(92.56±31.39),(5.22±0.57)] (P＜0.05).There was no statistically significant difference in the rate of adverse reactions between the control group and the experimental group (14.81％ vs.12.00％) (P＞0.05).Conclusion Yuanhu Zhitong capsule combined with sodium hyaluronate has obvious effect in patients with osteoarthritis,which can improve the score of joint function,relieve the pain of the patients,is another choice to treat the osteoarthritis patients with Chinese medicine.
展开▼
